A batch of new drugs for lung cancer and cerebrovascular disease break foreign monopoly or fill domestic gaps

Wang Chen, deputy director of the science and Education Department of the health and Family Planning Commission, said at today's conference that China has developed a number of high-quality and low-cost new drugs for major diseases such as lung cancer and cerebrovascular disease, breaking the monopoly of foreign drug market or filling the domestic gap in some areas There are 17 innovative or technological transformation varieties for the treatment of cerebrovascular diseases, and more than 35 million patients have been treated Wang Chen said that the national health and Family Planning Commission and the Ministry of health of the post general committee of the people's Republic of China took the lead in organizing the implementation of the "major new drug creation" project (hereinafter referred to as the "new drug project") and the "prevention and control of major infectious diseases such as AIDS and viral hepatitis" (hereinafter referred to as the "infectious disease project") since 2008 At present, remarkable achievements have been made in the research and development of new drugs A batch of new drugs with high quality and low price have been developed for major diseases, including 82 new drug certificates and 118 clinical approvals, which have broken the monopoly of foreign drug market or filled in the domestic gap in some fields For example, we have developed 17 innovative or technological transformation varieties, such as cetinib hydrochloride for lung cancer treatment, and butylphthalide injection for cerebrovascular disease, which has treated more than 35 million patients, made important contributions to meet the clinical needs and achieved good treatment results In addition, the special support for new drugs has exceeded 15.3% of national essential drugs for technological transformation That is to say, 15.3% of the national basic drugs are supported by the new drug project, which effectively improves the product quality, reduces the production cost, and provides a key guarantee for the implementation of the basic drug policy.